- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01463163
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a single-center, randomized, single-blind, investigator-initiated, pharmacodynamic study with a parallel design. Patients with ST elevation myocardial infarction, undergoing primary percutaneous coronary intervention will be randomized after informed consent, in a 1:1 ratio to the following treatment groups:
Group Α: Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD)starting 12±6 hours post LD, until Day 5 (5 days after randomization) Group Β: Prasugrel 60 mg LD followed by 10mg x1 MD starting 24 hours post LD, until Day 5 (5 days after randomization).
Platelet reactivity assessment will be performed at randomization (Hour 0) and at 1, 2, 6, 24 hours after randomization, and on Day 5. Documentation of major adverse cardiac events (death, myocardial infarction, stroke, revascularization procedure with PCI or CABG)and serious adverse events (bleeding, other adverse events)will be performed until Day 5.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
Achaia
-
Rio, Achaia, Grekland, 26500
- Cardiology Department Patras University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥18 years old
- Patients with STEMI undergoing primary PCI with stenting
- Informed consent obtained in writing
Exclusion Criteria:
- Pregnancy
- Breastfeeding
- Inability to give informed consent or high likelihood of being unavailable until the Day 5
- Prior PCI performed within 30 days prior to randomization
- Cardiogenic shock
- Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).
- Unsuccessful PCI (residual stenosis > 30% or flow < ΤΙΜΙ 3) or planned staged PCI in the next 5 days after randomization
- Requirement for oral anticoagulant prior to the Day 5 visit
- Current or planned therapy with other thienopyridine class of ADP receptor inhibitors.
- Known hypersensitivity to prasugrel or ticagrelor
- History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.
- Other bleeding diathesis, or considered by investigator to be at high risk for bleeding.
- Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
- Thombocytopenia (<100.000 / μL) at randomization
- Anaemia (Hct <30%) at randomization
- Polycytaemia (Hct > 52%) at randomization
- Periprocedural IIb/IIIa inhibitors administration
- Severe allergy to contrast agent, unfractionated heparin, enoxaparin or bivalirudin that cannot be adequately premedicated.
- Recent (< 6 weeks) major surgery or trauma, including GABG.
- Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
- Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine).
- Increased risk of bradycardiac events.
- Dialysis required.
- Severe uncontrolled chronic obstructive pulmonary disease
- Known severe hepatic impairement
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Prasugrel
Prasugrel 60mg LD followed by 10mg MD starting post 24 hours
|
Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
|
Experimentell: Ticagrelor
Ticagrelor 180mg LD followed by 90mg x2 MD starting post 12±6 hours
|
Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Platelet reactivity
Tidsram: 1hour
|
Platelet reactivity Platelet assessed by VerifyNow P2Y12 assay 1 hour post randomization
|
1hour
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Platelet reactivity
Tidsram: 1 hour
|
Platelet Reactivity assessed by Multiplate analyzer assay 1 hour post randomization
|
1 hour
|
Platelet reactivity
Tidsram: 2 hours
|
Platelet reactivity assessed by the VerifyNow assay 2 hours post randomization
|
2 hours
|
Platelet reactivity
Tidsram: 2 hours
|
Platelet Reactivity assessed by Multiplate analyzer 2 hours post randomization
|
2 hours
|
Platelet reactivity
Tidsram: 6 hours
|
Platelet Reactivity assessed by VerifyNow P2Y12 assay 6 hours post randomization
|
6 hours
|
Platelet reactivity
Tidsram: 6 hours
|
Platelet Reactivity assessed by Multiplate analyzer 6 hours post randomization
|
6 hours
|
Platelet reactivity
Tidsram: 24 hours
|
Platelet Reactivity assessed by VerifyNow P2Y12 assay 24 hours post randomization
|
24 hours
|
Platelet reactivity
Tidsram: 24 hours
|
Platelet Reactivity assessed by Multiplate analyzer 24 hours post randomization
|
24 hours
|
Platelet reactivity
Tidsram: 5 days
|
Platelet Reactivity assessed by VerifyNow P2Y12 assay 5 days post randomization
|
5 days
|
Platelet reactivity
Tidsram: 5 days
|
Platelet Reactivity assessed by Multiplate analyzer 5 days post randomization
|
5 days
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Ischemi
- Patologiska processer
- Nekros
- Myokardischemi
- Hjärtsjukdom
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Hjärtinfarkt
- Infarkt
- ST Elevation hjärtinfarkt
- Läkemedels fysiologiska effekter
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Trombocytaggregationshämmare
- Purinerga P2Y-receptorantagonister
- Purinerga P2-receptorantagonister
- Purinerga antagonister
- Purinerga medel
- Ticagrelor
- Prasugrel hydroklorid
Andra studie-ID-nummer
- PATRASCARDIOLOGY-8
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Trombocytreaktivitet
-
Taipei City HospitalAvslutadPRU (Platelet Reactivity Unit) | APT (Antiplatelet Therapy) | HOTPR (High on Treat Platelet Reactivity)Taiwan
-
Assiut UniversityHar inte rekryterat ännuPlatelet Storage Lesion (PSL)
Kliniska prövningar på Prasugrel
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.Avslutad
-
Gyeongsang National University HospitalAvslutadBlödning | Akut koronarsyndrom | TrombocyttrombosKorea, Republiken av
-
University of MilanAvslutad
-
University of PatrasAvslutad
-
Medstar Health Research InstituteAvslutadAkut koronarsyndromFörenta staterna
-
University of FloridaAvslutadKranskärlssjukdomFörenta staterna
-
VA Office of Research and DevelopmentAvslutadKranskärlsbypassFörenta staterna
-
Eli Lilly and CompanyAvslutad
-
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo CompanyAvslutadAkut kranskärlssyndrom (ACS)Taiwan